TerminatedNCT00997087
A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of OCD
Medication studyAges 19–60United States
Understand this study
Who could participate?
This study is for people with OCD. Listed age limits: 19 years to 60 years. Other eligibility criteria apply.
- Listed locations
- BirminghamSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 2009
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 11
- Sponsor
- Parkway Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 19 Years to 60 Years
- Official registry ID
- NCT00997087
- Official title
Show the full official title
Phase IIa A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder.
Recruitment & locations
TerminatedBirmingham
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Parkway Medical Center, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Flumazenil.
Who can participate?
This study is for people with OCD. Listed age limits: 19 years to 60 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
